Trials / Terminated
TerminatedNCT01849796
Transcranial Stimulation (tDCS) For the Treatment of Neuropathic Facial Pain
Transcranial Stimulation (TDCS) For The Treatment of Neuropathic Facial Pain.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Beth Israel Medical Center · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Accepted
Summary
A study to determine if transcranial direct current stimulation (tDCS, the device that regulates brain activity, can improve pain in people with neuropathic facial pain and compare which modality (inhibitory tDCS over the somatosensory cortex or excitatory tDCS over the motor cortex) can result in better pain-relief.)
Detailed description
This is a pilot study designed to collect preliminary data on safety and efficacy of transcranial direct current stimulation (tDCS)to relieve pain in subjects with neuropathic facial pain,and to compare two pain-treatment tDCS modalities: inhibitory tDCS stimulation over the somatosensory cortex and excitatory tDCS over the motor cortex.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | tDCS | TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes. |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2013-05-09
- Last updated
- 2015-12-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01849796. Inclusion in this directory is not an endorsement.